Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Abstract:
On Thursday, October 2, 2008, Dr. Tamarkin will be a featured speaker from 10:30-12:30 in the medicine and biology track at NanoTx08. His speech will focus on the recent Phase I CYT-6091 cancer patient trial in which the Company's gold nanomedicine was used to deliver a potent, but toxic, anti-cancer therapeutic to solid tumors. Such tumor targeting is best accomplished by avoiding uptake by the immune system and by limiting the biodistribution of the drug to the tumor. CYT-6091 accomplishes this by binding the potent, but toxic molecule TNF to the surface of PEGylated colloidal gold nanoparticles. TNF's toxicity is so severe that its clinical use is limited to isolated limb perfusion (ILP), where 1 mg of TNF followed by doxorubicin results in a 60-85% local response rate. In the completed CYT-6091 Phase I dose escalation clinical trial a similar dose of TNF was injected systemically. The treatment was well-tolerated, showing no dose limiting toxicity, and patient biopsies taken 24-hours after treatment showed gold nanoparticles in patient tumors. Multiple Phase II combination trials are planned.

The Promise of Tomorrow, A NanoTexas Radio Interview with Dr. Tamarkin

Rockville, MD | Posted on September 30th, 2008

####

About CytImmune Sciences, Inc.
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies. Based on an R&D strategy which harnesses the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the Company is developing a pipeline of proprietary drug candidates binding potent anti-cancer agents -- whose toxicity profiles currently prevent or severely limit clinical use -- to its patented colloidal gold tumor-targeting nanotechnology.

Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a patented, semi-synthetic in vitro immune system capable of producing fully-human monoclonal antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to create a separate class of nanomedicines.

For more information, please click here

Contacts:
CytImmune Sciences
9640 Medical Center Drive
Rockville, MD 20850
Phone: (240)-864-2796
Fax: (301) 315-2438

Copyright © CytImmune Sciences, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Ultra-thin optical fibers offer new way to 3-D print microstructures: Novel approach lays groundwork for using 3-D printing to repair tissue in the body January 17th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Announcements

New Method Uses DNA, Nanoparticles and Top-Down Lithography to Make Optically Active Structures: Technique could lead to new classes of materials that can bend light, such as for those used in cloaking devices January 18th, 2018

Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock January 18th, 2018

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock January 17th, 2018

Events/Classes

Leti to Demo New Curving Technology at Photonics West that Improves Performance of Optical Components January 18th, 2018

21st International Conference on Advanced Nanoscience and Nanotechnology December 31st, 2017

Leti Will Demonstrate First 3D Anti-Crash Solution for Embedding in Drones: Fitted on a Mass-Market Microcontroller, 360Fusion Software Technology Detects any Dynamic Obstacle and Helps Guide Drones Away from Collisions December 15th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project